Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Children worldwide still lack access to medicines designed for their needs — and the WHO-hosted Global Accelerator for Paediatric Formulations Network (GAP-f) is working to change that. On World Children's Day, GAP-f reaffirmed its Strategic Roadmap 2025–2030, targeting 10 high-burden diseases, 10 priority medicines, and stronger paediatric medicine ecosystems in 10 countries by 2030. Progress is happening, but sustained investment and collaboration remain critical.
Children worldwide still lack access to medicines specifically designed for their needs — and the WHO-hosted Global Accelerator for Paediatric Formulations Network (GAP-f) is working to change that. On World Children's Day, GAP-f reaffirmed its Strategic Roadmap 2025–2030, a shared framework aimed at accelerating the development, evidence generation, and access to age-appropriate medicines for children globally.
The network's "30 by '30" commitment targets three key goals by 2030: assessing priorities across 10 high-burden diseases, accelerating 10 priority medicines, and strengthening paediatric medicines ecosystems in 10 countries. In May 2026, WHO and GAP-f partners held a regional workshop in South-East Asia, bringing together four pilot countries to identify barriers and practical solutions for improving paediatric medicine access at the national level.
Key Takeaways:
Why it matters: Millions of children receive medicines formulated for adults — an approach that can be unsafe and ineffective. GAP-f's coordinated global effort aims to ensure that scientific innovation actually reaches children, regardless of where they live.